Electrodiagnostic Evaluation of Myopathies

Physical Medicine and Rehabilitation Clinics of North America

Volumn 24, Issue 1, 2013, Pages 193-207

  Paganoni, Sabrina ^a   Amato, Anthony ^b  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Electromyography; Motor unit action potential; Muscle biopsy; Muscle membrane irritability; Recruitment

Indexed keywords

AMPLITUDE MODULATION; CLINICAL EVALUATION; CORTICOSTEROID INDUCED MYOPATHY; DERMATOMYOSITIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; INCLUSION BODY MYOSITIS; MOTOR NERVE CONDUCTION; MOTOR UNIT POTENTIAL; MUSCULAR DYSTROPHY; MYOPATHY; MYOTONIC DYSTROPHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CONDUCTION; TOXIC MYOPATHY;

DERMATOMYOSITIS; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MUSCULAR DISEASES; MUSCULAR DYSTROPHIES; NEURAL CONDUCTION; PHYSICAL EXAMINATION; POLYNEUROPATHIES;

EID: 84869993428     PISSN: 10479651     EISSN: 15581381     Source Type: Journal    
DOI: 10.1016/j.pmr.2012.08.017     Document Type: Review

References (24)

1. Amato A.A., Russell J. Testing in neuromuscular disease-electrodiagnosis and other modalities. Neuromuscular disorders 2008, 17-69. McGraw-Hill, New York. 1st edition. A.M. Sydor, C. Naglieri (Eds.).
2. Preston D., Shapiro B. Myopathy. Electromyography and neuromuscular disorders 2005, 575-589. Elsevier, Philadelphia. 2nd edition. D. Preston, B. Shapiro (Eds.).
3. Oh S.J., Kurokawa K., Claussen G.C., et al. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005, 32(4):515-520.
4. Fournier E., Arzel M., Sternberg, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004, 56(5):650-661.
5. Fournier E., Viala K., Gervais H., et al. Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol 2006, 60(3):356-365.
6. Petajan J.H. AAEM minimonograph #3: motor unit recruitment. Muscle Nerve 1991, 14(6):489-502.
7. Daube J.R. AAEM minimonograph #11: needle examination in clinical electromyography. Muscle Nerve 1991, 14(8):685-700.
8. Nandedkar S.D., Stalberg E.V., Sanders D. Quantitative EMG. Electrodiagnostic medicine 2002, 293-356. Hanley & Belfus, Philadelphia. 2nd edition. D. Dumitru, A.A. Amato, M.J. Swartz (Eds.).
9. Cardamone M., Darras B.T., Ryan M.M. Inherited myopathies and muscular dystrophies. Semin Neurol 2008, 28(2):250-259.
10. Hoffman E.P., Fischbeck K.H., Brown R.H., et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988, 318(21):1363-1368.
11. Emeryk-Szajewska B., Kopeć J. Electromyographic pattern in duchenne and becker muscular dystrophy. Part I: electromyographic pattern in subsequent stages of muscle lesion in duchenne muscular dystrophy. Electromyogr Clin Neurophysiol 2008, 48(6-7):265-277.
12. Emeryk-Szajewska B., Kopeć J. Electromyographic pattern in duchenne and becker muscular dystrophy. Part II. Electromyographic pattern in becker muscular dystrophy in comparison with duchenne muscular dystrophy. Electromyogr Clin Neurophysiol 2008, 48(6-7):279-284.
13. Amato A.A., Barohn R.J. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009, 80(10):1060-1068.
14. Buchthal F., Pinelli P. Muscle action potentials in polymyositis. Neurology 1953, 3(6):424-436.
15. Lotz B.P., Engel A.G., Nishino H., et al. Inclusion body myositis. Observations in 40 patients. Brain 1989, 112(Pt 3):727-747.
16. Joy J.L., Oh S.J., Baysal A.I. Electrophysiological spectrum of inclusion body myositis. Muscle Nerve 1990, 13(10):949-951.
17. Grable-Esposito P., Katzberg H.D., Greenberg S.A., et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41(2):185-190.
18. Meriggioli M.N., Barboi A.C., Rowin J., et al. HMG-CoA reductase inhibitor myopathy: clinical, electrophysiological, and pathologic data in five patients. J Clin Neuromuscul Dis 2001, 2(3):129-134.
19. Lacomis D., Petrella J.T., Giuliani M.J. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 1998, 21(5):610-617.
20. Lacomis D., Giuliani M.J., Van Cott A., et al. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996, 40(4):645-654.
21. Buchthal F. Electrophysiological abnormalities in metabolic myopathies and neuropathies. Acta Neurol Scand 1970, 46(Suppl 43):129+.
22. Hobson-Webb L.D., Dearmey S., Kishnani P.S. The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol 2011, 122(11):2312-2317.
23. Logigian E.L., Ciafaloni E., Quinn L.C., et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 2007, 35:479-485.
24. Matthews E., Fialho D., Tan S.V., CINCH Investigators, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 2010, 133(Pt 1):9-22.